MedPlus Health Services Limited (NSE: MEDPLUS.NS) Stock Competitors & Peer Comparison

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ABBOTINDIA.BO has a market cap of 553.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ABBOTINDIA.BO trades at ₹25,840.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ABBOTINDIA.BO's P/E ratio is 34.89. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ABBOTINDIA.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ABBOTINDIA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ABBOTINDIA.NS has a market cap of 550.5B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ABBOTINDIA.NS trades at ₹25,905.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ABBOTINDIA.NS's P/E ratio is 34.98. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ABBOTINDIA.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ABBOTINDIA.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check JBCHEPHARM.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check JBCHEPHARM.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, WOCKPHARMA.BO has a market cap of 310.4B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while WOCKPHARMA.BO trades at ₹1,906.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas WOCKPHARMA.BO's P/E ratio is 75.74. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to WOCKPHARMA.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check WOCKPHARMA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, WOCKPHARMA.NS has a market cap of 309.8B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while WOCKPHARMA.NS trades at ₹1,906.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas WOCKPHARMA.NS's P/E ratio is 75.74. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to WOCKPHARMA.NS's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to WOCKPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check WOCKPHARMA.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, MEDPLUS.BO has a market cap of 72B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while MEDPLUS.BO trades at ₹599.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas MEDPLUS.BO's P/E ratio is 31.86. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to MEDPLUS.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check MEDPLUS.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SUPRIYA.BO has a market cap of 70.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SUPRIYA.BO trades at ₹874.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SUPRIYA.BO's P/E ratio is 35.46. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SUPRIYA.BO's ROE of +0.17%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SUPRIYA.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SUPRIYA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SUPRIYA.NS has a market cap of 70.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SUPRIYA.NS trades at ₹873.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SUPRIYA.NS's P/E ratio is 33.59. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SUPRIYA.NS's ROE of +0.17%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SUPRIYA.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SUPRIYA.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SANOFI.BO has a market cap of 66.5B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SANOFI.BO trades at ₹2,881.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SANOFI.BO's P/E ratio is 18.98. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SANOFI.BO's ROE of +0.41%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SANOFI.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SANOFI.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SANOFI.NS has a market cap of 66.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SANOFI.NS trades at ₹2,880.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SANOFI.NS's P/E ratio is 18.97. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SANOFI.NS's ROE of +0.41%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SANOFI.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SANOFI.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, KPL.BO has a market cap of 34.8B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while KPL.BO trades at ₹3,356.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas KPL.BO's P/E ratio is 42.97. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to KPL.BO's ROE of +0.26%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check KPL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SHUKRAPHAR.BO has a market cap of 30.2B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SHUKRAPHAR.BO trades at ₹68.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SHUKRAPHAR.BO's P/E ratio is 88.61. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SHUKRAPHAR.BO's ROE of +0.44%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SHUKRAPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SHUKRAPHAR.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, HIKAL.NS has a market cap of 26.8B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while HIKAL.NS trades at ₹217.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas HIKAL.NS's P/E ratio is 15.55. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check HIKAL.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, HIKAL.BO has a market cap of 26.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while HIKAL.BO trades at ₹216.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas HIKAL.BO's P/E ratio is 188.17. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to HIKAL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check HIKAL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, FREDUN.BO has a market cap of 23.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while FREDUN.BO trades at ₹1,430.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas FREDUN.BO's P/E ratio is 56.28. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check FREDUN.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ACCENTMIC.NS has a market cap of 15.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ACCENTMIC.NS trades at ₹654.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ACCENTMIC.NS's P/E ratio is 27.59. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ACCENTMIC.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VIKRAMTH.BO has a market cap of 12B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VIKRAMTH.BO trades at ₹382.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VIKRAMTH.BO's P/E ratio is 27.37. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VIKRAMTH.BO's ROE of +0.30%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VIKRAMTH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BPLPHARMA.BO has a market cap of 11.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BPLPHARMA.BO trades at ₹1,728.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BPLPHARMA.BO's P/E ratio is -77.31. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to BPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BPLPHARMA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, REMUS.NS has a market cap of 11.6B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while REMUS.NS trades at ₹984.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas REMUS.NS's P/E ratio is 31.36. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to REMUS.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check REMUS.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BAFNAPH.NS has a market cap of 11.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BAFNAPH.NS trades at ₹470.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BAFNAPH.NS's P/E ratio is 142.97. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BAFNAPH.NS's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BAFNAPH.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BAFNAPH.BO has a market cap of 11.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BAFNAPH.BO trades at ₹477.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BAFNAPH.BO's P/E ratio is 145.20. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BAFNAPH.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to BAFNAPH.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BAFNAPH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SASTASUNDR.NS trades at ₹282.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SASTASUNDR.NS's ROE of -0.03%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SASTASUNDR.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SGRL.BO has a market cap of 8.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SGRL.BO trades at ₹691.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SGRL.BO's P/E ratio is 57.54. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SGRL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SGRL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SUDARSHAN.BO has a market cap of 8.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SUDARSHAN.BO trades at ₹35.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SUDARSHAN.BO's P/E ratio is 33.04. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SUDARSHAN.BO's ROE of +0.17%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SUDARSHAN.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SUDARSHAN.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ONEGLOBAL.BO has a market cap of 8.6B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ONEGLOBAL.BO trades at ₹452.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ONEGLOBAL.BO's P/E ratio is 11.63. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ONEGLOBAL.BO's ROE of +0.61%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ONEGLOBAL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ALBERTDA.BO's ROE of +0.06%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ALBERTDA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PRAVEG.BO has a market cap of 5.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PRAVEG.BO trades at ₹225.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PRAVEG.BO's P/E ratio is -31.17. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PRAVEG.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TRANSCHEM.BO has a market cap of 5.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TRANSCHEM.BO trades at ₹416.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TRANSCHEM.BO's P/E ratio is 110.54. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to TRANSCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TRANSCHEM.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TLL.BO has a market cap of 4.8B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TLL.BO trades at ₹402.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TLL.BO's P/E ratio is 22.45. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to TLL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TLL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, INFINIUM.NS has a market cap of 4.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while INFINIUM.NS trades at ₹294.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas INFINIUM.NS's P/E ratio is 38.41. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is less volatile compared to INFINIUM.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check INFINIUM.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, JENBURPH.BO has a market cap of 4.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while JENBURPH.BO trades at ₹925.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas JENBURPH.BO's P/E ratio is 12.44. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to JENBURPH.BO's ROE of +0.17%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to JENBURPH.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check JENBURPH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, AMBALALSA.BO has a market cap of 3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while AMBALALSA.BO trades at ₹38.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas AMBALALSA.BO's P/E ratio is 21.95. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check AMBALALSA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ZENOTECH.BO has a market cap of 2.6B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ZENOTECH.BO trades at ₹42.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ZENOTECH.BO's P/E ratio is -104.00. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ZENOTECH.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ZENOTECH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BDH.BO has a market cap of 2.5B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BDH.BO trades at ₹442.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BDH.BO's P/E ratio is 21.73. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BDH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, GENNEX.BO has a market cap of 2.2B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while GENNEX.BO trades at ₹8.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas GENNEX.BO's P/E ratio is 11.07. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to GENNEX.BO's ROE of +0.08%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check GENNEX.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SANJIVIN.BO has a market cap of 2.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SANJIVIN.BO trades at ₹172.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SANJIVIN.BO's P/E ratio is 28.90. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SANJIVIN.BO's ROE of +0.16%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SANJIVIN.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SANJIVIN.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, KERALAYUR.BO has a market cap of 1.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while KERALAYUR.BO trades at ₹146.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas KERALAYUR.BO's P/E ratio is -6.91. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to KERALAYUR.BO's ROE of -2.62%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check KERALAYUR.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SYSCHEM.BO has a market cap of 1.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SYSCHEM.BO trades at ₹35.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SYSCHEM.BO's P/E ratio is 585.33. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SYSCHEM.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, CORALAB.BO has a market cap of 1.9B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while CORALAB.BO trades at ₹524.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas CORALAB.BO's P/E ratio is 9.76. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check CORALAB.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while OXYGENTAPH.BO trades at ₹46.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas OXYGENTAPH.BO's P/E ratio is -12.69. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to OXYGENTAPH.BO's ROE of +0.34%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check OXYGENTAPH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SMRUTHIORG.BO has a market cap of 1.6B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SMRUTHIORG.BO trades at ₹141.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SMRUTHIORG.BO's P/E ratio is 21.75. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SMRUTHIORG.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, QUESTLAB.NS has a market cap of 1.5B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while QUESTLAB.NS trades at ₹90.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas QUESTLAB.NS's P/E ratio is 9.84. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to QUESTLAB.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check QUESTLAB.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, KIMIABL.BO has a market cap of 1.5B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while KIMIABL.BO trades at ₹31.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas KIMIABL.BO's P/E ratio is 20.41. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to KIMIABL.BO's ROE of +0.49%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to KIMIABL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check KIMIABL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, AUROLAB.BO has a market cap of 1.4B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while AUROLAB.BO trades at ₹231.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas AUROLAB.BO's P/E ratio is 30.80. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to AUROLAB.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check AUROLAB.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PANCHSHEEL.BO trades at ₹104.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PANCHSHEEL.BO's P/E ratio is 12.65. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to PANCHSHEEL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PANCHSHEEL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while LACTOSE.BO trades at ₹101.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas LACTOSE.BO's P/E ratio is 18.40. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to LACTOSE.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check LACTOSE.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, GODAVARI.BO has a market cap of 1.3B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while GODAVARI.BO trades at ₹122.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas GODAVARI.BO's P/E ratio is 28.41. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to GODAVARI.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check GODAVARI.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PARNAXLAB.BO has a market cap of 1.2B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PARNAXLAB.BO trades at ₹108.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PARNAXLAB.BO's P/E ratio is 13.94. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to PARNAXLAB.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PARNAXLAB.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, MAKERSL.BO has a market cap of 1.2B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while MAKERSL.BO trades at ₹205.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas MAKERSL.BO's P/E ratio is 35.47. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check MAKERSL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PHARMAID.BO trades at ₹31.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PHARMAID.BO's P/E ratio is -24.17. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PHARMAID.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TYCHE.BO trades at ₹103.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TYCHE.BO's P/E ratio is 23.68. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TYCHE.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SOTAC.NS trades at ₹90.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SOTAC.NS's P/E ratio is 17.24. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SOTAC.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, MERCURYLAB.BO has a market cap of 894.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while MERCURYLAB.BO trades at ₹745.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas MERCURYLAB.BO's P/E ratio is 21.49. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check MERCURYLAB.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, DENISCHEM.BO has a market cap of 869.2M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while DENISCHEM.BO trades at ₹62.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas DENISCHEM.BO's P/E ratio is 10.89. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to DENISCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check DENISCHEM.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VAISHALI.NS has a market cap of 803.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VAISHALI.NS trades at ₹7.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VAISHALI.NS's P/E ratio is 23.36. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VAISHALI.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, CONCORD.BO has a market cap of 755.2M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while CONCORD.BO trades at ₹68.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas CONCORD.BO's P/E ratio is 40.48. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to CONCORD.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to CONCORD.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check CONCORD.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VILINBIO.NS has a market cap of 742.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VILINBIO.NS trades at ₹53.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VILINBIO.NS's P/E ratio is 41.79. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is less volatile compared to VILINBIO.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VILINBIO.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SUNLOC.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SUNLOC.BO's P/E ratio is 20.16. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SUNLOC.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SUNLOC.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SOURCENTRL.BO has a market cap of 701.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SOURCENTRL.BO trades at ₹109.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SOURCENTRL.BO's P/E ratio is 20.64. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SOURCENTRL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ZENITHDRUG.NS has a market cap of 668.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ZENITHDRUG.NS trades at ₹39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ZENITHDRUG.NS's P/E ratio is 16.96. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ZENITHDRUG.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ZENITHDRUG.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PHRMASI.BO has a market cap of 546.2M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PHRMASI.BO trades at ₹80.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PHRMASI.BO's P/E ratio is 3.11. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PHRMASI.BO's ROE of +1.07%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to PHRMASI.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PHRMASI.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SHELTER.BO has a market cap of 544.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SHELTER.BO trades at ₹47.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SHELTER.BO's P/E ratio is 8.72. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SHELTER.BO's ROE of +0.13%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SHELTER.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PARMAX.BO has a market cap of 510.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PARMAX.BO trades at ₹136.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PARMAX.BO's P/E ratio is -44.29. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PARMAX.BO's ROE of +0.22%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PARMAX.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ANG.BO has a market cap of 493M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ANG.BO trades at ₹37.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ANG.BO's P/E ratio is -3.70. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ANG.BO's ROE of -0.23%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ANG.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ANG.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VRL.BO has a market cap of 432.4M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VRL.BO trades at ₹136.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VRL.BO's P/E ratio is 7.46. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to VRL.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VRL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BIBCL.BO has a market cap of 412.4M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BIBCL.BO trades at ₹9.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BIBCL.BO's P/E ratio is -3.77. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BIBCL.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, MEDIORG.NS has a market cap of 398M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while MEDIORG.NS trades at ₹26.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas MEDIORG.NS's P/E ratio is -7.84. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to MEDIORG.NS. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check MEDIORG.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VISTAPH.BO has a market cap of 376.1M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VISTAPH.BO trades at ₹6.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VISTAPH.BO's P/E ratio is -3.17. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VISTAPH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PANJON.BO has a market cap of 350.2M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PANJON.BO trades at ₹20.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PANJON.BO's P/E ratio is 127.50. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PANJON.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ROOPAIND.BO has a market cap of 341.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ROOPAIND.BO trades at ₹43.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ROOPAIND.BO's P/E ratio is 333.77. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ROOPAIND.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SANDUPHQ.BO has a market cap of 339.4M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SANDUPHQ.BO trades at ₹35.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SANDUPHQ.BO's P/E ratio is 19.30. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SANDUPHQ.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, MEDICAPQ.BO has a market cap of 320.5M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while MEDICAPQ.BO trades at ₹25.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas MEDICAPQ.BO's P/E ratio is -18.02. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to MEDICAPQ.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check MEDICAPQ.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, DECCAN.BO has a market cap of 315.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while DECCAN.BO trades at ₹12.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas DECCAN.BO's P/E ratio is 12.49. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check DECCAN.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BACPHAR.BO has a market cap of 291.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BACPHAR.BO trades at ₹20.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BACPHAR.BO's P/E ratio is 68.12. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BACPHAR.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BACPHAR.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, GUJTERC.BO has a market cap of 273.1M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while GUJTERC.BO trades at ₹35.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas GUJTERC.BO's P/E ratio is 12.66. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to GUJTERC.BO's ROE of +0.24%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check GUJTERC.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TRIMURTHI.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TRIMURTHI.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, WELCURE.BO has a market cap of 234.8M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while WELCURE.BO trades at ₹0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas WELCURE.BO's P/E ratio is -9.44. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check WELCURE.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ISHITADR.BO has a market cap of 232.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ISHITADR.BO trades at ₹77.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ISHITADR.BO's P/E ratio is 32.93. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ISHITADR.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ISHITADR.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to CHEMOPH.BO's ROE of +0.03%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check CHEMOPH.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ZENLABS.BO has a market cap of 178.1M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ZENLABS.BO trades at ₹27.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ZENLABS.BO's P/E ratio is -7.30. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ZENLABS.BO's ROE of -0.27%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ZENLABS.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, COLINZ.BO has a market cap of 176.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while COLINZ.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas COLINZ.BO's P/E ratio is 6.31. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check COLINZ.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SUNREST.NS has a market cap of 161.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SUNREST.NS trades at ₹37.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SUNREST.NS's P/E ratio is 4.34. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SUNREST.NS's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, NORRIS.BO has a market cap of 160M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while NORRIS.BO trades at ₹16.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check NORRIS.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, SHAMROIN.BO has a market cap of 147.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while SHAMROIN.BO trades at ₹27.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas SHAMROIN.BO's P/E ratio is -13.79. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to SHAMROIN.BO's ROE of -1.27%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check SHAMROIN.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, BERLDRG.BO has a market cap of 126M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while BERLDRG.BO trades at ₹24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas BERLDRG.BO's P/E ratio is 20.17. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check BERLDRG.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, EMMESSA.BO has a market cap of 106.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while EMMESSA.BO trades at ₹21.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas EMMESSA.BO's P/E ratio is 26.33. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to EMMESSA.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check EMMESSA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, KOBO.BO has a market cap of 101.7M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while KOBO.BO trades at ₹4.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas KOBO.BO's P/E ratio is -1.56. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check KOBO.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, ADLINE.BO has a market cap of 92.4M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while ADLINE.BO trades at ₹15.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check ADLINE.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, GANGAPHARM.BO has a market cap of 73.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while GANGAPHARM.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas GANGAPHARM.BO's P/E ratio is 73.53. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check GANGAPHARM.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TRINITYLEA.BO has a market cap of 73.7M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TRINITYLEA.BO trades at ₹9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TRINITYLEA.BO's P/E ratio is -54.76. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TRINITYLEA.BO's ROE of -0.05%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to TRINITYLEA.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TRINITYLEA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, HINDBIO.BO has a market cap of 71.3M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while HINDBIO.BO trades at ₹6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas HINDBIO.BO's P/E ratio is -34.63. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to HINDBIO.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check HINDBIO.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, VIVANZA.BO has a market cap of 67.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while VIVANZA.BO trades at ₹1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas VIVANZA.BO's P/E ratio is 14.88. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to VIVANZA.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check VIVANZA.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TIAANC.BO trades at ₹6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TIAANC.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, DECIPHER.BO has a market cap of 55.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while DECIPHER.BO trades at ₹5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas DECIPHER.BO's P/E ratio is -1.82. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, MEDPLUS.NS is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for MEDPLUS.NS.Check DECIPHER.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, TMTIND-B1.BO has a market cap of 43.9M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while TMTIND-B1.BO trades at ₹8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas TMTIND-B1.BO's P/E ratio is -177.40. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, MEDPLUS.NS is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check TMTIND-B1.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while FABINO.BO trades at ₹20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check FABINO.BO's competition here

MedPlus Health Services Limited (NSE: MEDPLUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MEDPLUS.NS stands at 72B. In comparison, PATIDAR.BO has a market cap of 35.6M. Regarding current trading prices, MEDPLUS.NS is priced at ₹599.35 on the NSE, while PATIDAR.BO trades at ₹6.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MEDPLUS.NS currently has a P/E ratio of 32.43, whereas PATIDAR.BO's P/E ratio is -15.43. In terms of profitability, MEDPLUS.NS's ROE is +0.11%, compared to PATIDAR.BO's ROE of -0.03%. Regarding short-term risk, MEDPLUS.NS is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for MEDPLUS.NS.Check PATIDAR.BO's competition here